血清乙肝病毒核心抗体定量检测在慢性乙肝患者病情评价中的应用价值  

Application value of serum hepatitis B virus core antibody in the evaluation of chronic hepatitis B patients’ condition

作　　者：王月云[1] 王骥[1] WANG Yue-yun;WANG Ji(Department of Hepatitis,Xuzhou Infectious Disease Hospital,Xuzhou 221000,China)

机构地区：[1]徐州市传染病医院肝炎一科,江苏徐州221000

出　　处：《中国处方药》2023年第2期171-174,共4页Journal of China Prescription Drug

摘　　要：目的 探讨血清乙肝病毒核心抗体定量检测在慢性乙肝患者病情评价中的应用价值。方法 选取2019年3月~2021年5月某院门诊部和住院部收治的128例慢性乙肝病毒感染患者为研究对象,上述患者分为慢性乙型肝炎组(CHB组,n=72)和肝硬化组(LC组,n=56)。比较两组血清HBcAb定量滴度与HBV血清标志物、血清生化指标和肝脏纤维化程度的关系。结果 LC组HBsAg的定量滴度显著低于CHB组(P <0.05),HBcAb和HBV-DNA的定量滴度显著高于CHB组(P <0.05)。LC组的ALT、AST、ALB值显著低于CHB组(P <0.05),TBil值明显高于CHB组。LC组HBcAb滴度水平与HBV-DNA无显著相关性(r=-0.010, P> 0.05),与ALT呈显著正相关(r=0.316, P <0.05)。LC组的HBsAg和HBcAb的滴度水平与未出现肝纤维化组、轻度纤维化组、中度纤维化组和重度纤维化组的差异具有统计学意义(P <0.05)。HBV感染患者的肝纤维化发展程度与其HBsAg滴度水平呈负相关(r=-0.697,P=0.003),与其HBcAb滴度水平呈正相关(r=0.816,P=0.001)。结论 血清HBcAb定量可作为早期乙肝患者HBV感染和肝脏纤维化病情发展程度的预测指标,可与HBV-DNA、ALT等HBV血清标志物联合评估患者肝炎程度,为乙肝患者的临床病情评价提供参考。Objective To explore the application value of serum chronic hepatitis B virus core antibody in the evaluation of hepatitis B patients’ condition. Methods From March 2019 to May 2021, 128 cases of chronic hepatitis B virus infection admitted to outpatient department and inpatient department were selected as the research subjects. The above patients were divided into chronic hepatitis B group(CHB,n = 72) and liver cirrhosis group(LC,n = 56). The relationship between serum HBcAb and serum HBV markers, serum biochemical parameters and liver fibrosis were compared between the two groups. Results The quantitative titer of HBsAg in LC group was significantly lower than that in CHB group(P <0.05), and the quantitative titer of HBcAb and HBV-DNA was significantly higher than that in CHB group(P < 0.05). There was no significant correlation between HBcAb titer and HBV DNA in LC group(r =-0.010, P > 0.05), but there was a significant positive correlation between HBcAb titer and ALT(r = 0.316, P < 0.05).The titers of HBsAg and HBcAb in liver cirrhosis group were significantly different from those in non liver fibrosis group, mild fibrosis group, moderate fibrosis group and severe fibrosis group(P < 0.05).The development of liver fibrosis in patients with HBV infection was negatively correlated with its HBsAg titer(r =-0.697, P = 0.003) and its HBcAb titer was positively correlated(r = 0.816, P = 0.001). Conclusion Serum HBcAb quantification can be used as a predictor of the development of HBV infection and liver fibrosis in patients with early hepatitis B, and can be combined with HBV-DNA, ALT and AST to assess the degree of hepatitis in patients, so as to provide reference for clinical evaluation of hepatitis B patients.

关 键 词：血清乙肝病毒核心抗体 抗体定量 乙肝 肝硬化 

分 类 号：R512.62[医药卫生—内科学]